DOCETAXEL IN THE FIRST-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS VERSUS VINORELBINE FROM THE TAX 326 TRIAL

被引：0
|
作者：
Baillot, S. [1 ]
de Pouvourville, G. [2 ]
Morais, E. [3 ]
Scharzinger, M. [1 ]
Fossella, F. [4 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] ESSEC, Chaire Sante, Cergy Pontoise, France
[3] Sanofi Aventis R&D, Hlth Econ & Reimbursement, Paris, France
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：227 / 227
页数：1
相关论文
共 50 条
  • [1] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
  • [2] Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (04) : 325 - 335
  • [3] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL, PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN RUSSIA
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A.
    VALUE IN HEALTH, 2011, 14 (07) : A450 - A450
  • [4] First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    BMJ OPEN, 2023, 13 (12):
  • [5] Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
    Wang, Yao
    Huang, Kaiyu
    Sun, Sijia
    Deng, Yahong
    Xie, Xuefeng
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2022, 15 : 351 - 359
  • [6] Cost-effectiveness analysis of endoscopic ultrasound as a first-line staging tool for patients with non-small-cell lung cancer
    Lai, L. H.
    Hsin, M. K.
    Tse, Y. K.
    Chan, F. K. L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A7 - A7
  • [7] Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China
    Zhang, Xiaoyu
    Fan, Xiongxiong
    Zhang, Jin
    Jiang, Fengli
    Wu, Yiping
    Yang, Beibei
    Li, Xinghuan
    Liu, Dong
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [8] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [9] Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
    Lu, Shun
    Yu, Yongfeng
    Fu, Shijun
    Ren, Hongye
    PLOS ONE, 2018, 13 (10):
  • [10] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
    Khan, Iftekhar
    Morris, Stephen
    Hackshaw, Allan
    Lee, Siow-Ming
    BMJ OPEN, 2015, 5 (07):
12345